Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma.
Gene expression
Gene signature
Immunoprofiling
NSCLC
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
03 07 2020
03 07 2020
Historique:
received:
29
04
2020
accepted:
24
06
2020
entrez:
5
7
2020
pubmed:
6
7
2020
medline:
15
5
2021
Statut:
epublish
Résumé
The tumor immune microenvironment is a heterogeneous entity. Gene expression analysis allows us to perform comprehensive immunoprofiling and may assist in dissecting the different components of the immune infiltrate. As gene expression analysis also provides information regarding tumor cells, differences in interactions between the immune system and specific tumor characteristics can also be explored. This study aims to gain further insights in the composition of the tumor immune infiltrate and to correlate these components to histology and overall survival in non-small cell lung cancer (NSCLC). Archival tissues from 530 early stage, resected NSCLC patients with annotated tumor and patient characteristics were analyzed using the NanoString nCounter Analysis system. Unsupervised clustering of the samples was mainly driven by the overall level of inflammation, which was not correlated with survival in this patient set. Adenocarcinoma (AD) showed a significantly higher degree of immune infiltration compared to squamous cell carcinoma (SCC). A 34-gene signature, which did not correlate with the overall level of immune infiltration, was identified and showed an OS benefit in SCC. Strikingly, this benefit was not observed in AD. This difference in OS in SCC specifically was confirmed in two independent NSCLC cohorts. The highest correlation between expression of the 34-gene signature and specific immune cell populations was observed for NK cells, but although a plausible mechanism for NK cell intervention in tumor growth could be established in SCC over AD, this could not be translated back to immunohistochemistry, which showed that NK cell infiltration is scarce irrespective of histology. These findings suggest that the ability of immune cell infiltration and the interaction between tumor and immune cells may be different between AD and SCC histology and that a subgroup of SCC tumors seems more susceptible to Natural Killer cell recognition and killing, whereas this may not occur in AD tumors. A highly sensitive technique like NanoString was able to detect this subgroup based on a 34-gene signature, but further research will be needed to assist in explaining the biological rationale of such low-level expression signatures.
Sections du résumé
BACKGROUND
The tumor immune microenvironment is a heterogeneous entity. Gene expression analysis allows us to perform comprehensive immunoprofiling and may assist in dissecting the different components of the immune infiltrate. As gene expression analysis also provides information regarding tumor cells, differences in interactions between the immune system and specific tumor characteristics can also be explored. This study aims to gain further insights in the composition of the tumor immune infiltrate and to correlate these components to histology and overall survival in non-small cell lung cancer (NSCLC).
METHODS
Archival tissues from 530 early stage, resected NSCLC patients with annotated tumor and patient characteristics were analyzed using the NanoString nCounter Analysis system.
RESULTS
Unsupervised clustering of the samples was mainly driven by the overall level of inflammation, which was not correlated with survival in this patient set. Adenocarcinoma (AD) showed a significantly higher degree of immune infiltration compared to squamous cell carcinoma (SCC). A 34-gene signature, which did not correlate with the overall level of immune infiltration, was identified and showed an OS benefit in SCC. Strikingly, this benefit was not observed in AD. This difference in OS in SCC specifically was confirmed in two independent NSCLC cohorts. The highest correlation between expression of the 34-gene signature and specific immune cell populations was observed for NK cells, but although a plausible mechanism for NK cell intervention in tumor growth could be established in SCC over AD, this could not be translated back to immunohistochemistry, which showed that NK cell infiltration is scarce irrespective of histology.
CONCLUSIONS
These findings suggest that the ability of immune cell infiltration and the interaction between tumor and immune cells may be different between AD and SCC histology and that a subgroup of SCC tumors seems more susceptible to Natural Killer cell recognition and killing, whereas this may not occur in AD tumors. A highly sensitive technique like NanoString was able to detect this subgroup based on a 34-gene signature, but further research will be needed to assist in explaining the biological rationale of such low-level expression signatures.
Identifiants
pubmed: 32620126
doi: 10.1186/s12967-020-02436-3
pii: 10.1186/s12967-020-02436-3
pmc: PMC7333331
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
271Références
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Cancer Immunol Res. 2019 Jul;7(7):1162-1174
pubmed: 31088844
Genome Biol. 2014;15(12):550
pubmed: 25516281
Lung Cancer. 2002 Jan;35(1):23-8
pubmed: 11750709
Oncotarget. 2019 Dec 24;10(67):7142-7155
pubmed: 31903172
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
J Thorac Oncol. 2016 Jun;11(6):789-800
pubmed: 26845192
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
PLoS One. 2019 May 24;14(5):e0216864
pubmed: 31125352
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nat Rev Immunol. 2007 Sep;7(9):703-14
pubmed: 17717540
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Front Immunol. 2016 Apr 21;7:152
pubmed: 27148271
J Clin Oncol. 2010 Oct 10;28(29):4417-24
pubmed: 20823422
Lung Cancer. 2012 Jun;76(3):445-51
pubmed: 22300751
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Annu Rev Immunol. 2011;29:235-71
pubmed: 21219185
Adv Immunol. 1989;47:187-376
pubmed: 2683611
Clin Cancer Res. 2008 Nov 15;14(22):7397-404
pubmed: 19010856
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973